Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Riboflavin 0.1% Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Refractory Corneal Infection

NCT02068430
View directory record Official record
Conditions
Corneal Ulcers
Interventions
Riboflavin 0.1%, UV-X™ Illumination System
Drug · Other
Lead sponsor
Stephen Trokel
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 2Phase 3 Interventional

Comparison of Standard vs. Accelerated Corneal Crosslinking

NCT03922542
View directory record Official record
Conditions
Keratoconus, Ectasia Corneal
Interventions
Riboflavin 0.1%
Combination Product
Lead sponsor
Price Vision Group
Industry
Eligibility
10 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Corneal Collagen Cross-Linking for Ectasia (CXL)

NCT00674661
View directory record Official record
Conditions
Ectasia
Interventions
riboflavin ophthalmic solution, UVA Irradiation
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
14 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
La Jolla, California • San Diego, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 24, 2026, 4:04 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

NCT01325298
View directory record Official record
Conditions
Keratoconus, Ectasia, Corneal Ectasia
Interventions
UV-X Light, Riboflavin
Device · Drug
Lead sponsor
Mercy Center for Corrective Eye Surgery
Other
Eligibility
14 Years to 55 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
McHenry, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 3 Interventional

Steroids and Cross-linking for Ulcer Treatment

NCT04097730
View directory record Official record
Conditions
Keratitis Bacterial
Interventions
Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Topical Placebo
Drug · Other
Lead sponsor
Thomas M. Lietman
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Early Phase 1 Interventional

Intravenous Plasma Treatment for Parkinson's Disease

NCT04202757
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
[21CFR640.30] Plasma from 18 - 25 year old volunteer donors, Saline
Biological · Other
Lead sponsor
The Neurology Center
Other
Eligibility
45 Years to 90 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Sep 24, 2026, 4:04 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Riboflavin/Dextran or Riboflavin/Methylcellulose

NCT04897503
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
12 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia

NCT01143389
View directory record Official record
Conditions
Keratoconus, Post-Refractive Ectasia
Interventions
Riboflavin, UVX light
Drug · Device
Lead sponsor
Price Vision Group
Industry
Eligibility
10 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

NCT01582880
View directory record Official record
Conditions
Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Systemic, Rheumatoid Arthritis, Other Autoimmune Diseases
Interventions
Riboflavin
Drug
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit

NCT02863809
View directory record Official record
Conditions
Keratolysis
Interventions
Riboflavin, Dextran, UVA Light Source
Drug · Device
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 24, 2026, 4:04 PM EDT
Not listed Phase 3 Interventional

Corneal Cross-Linking Comparing Variables

NCT02095730
View directory record Official record
Conditions
Unstable Corneas
Interventions
Epithelium-On Riboflavin, Epithelium-Off Riboflavin, UV Light - Continuous Beam, UV Pulsed Beam
Drug · Device
Lead sponsor
Crowd Health Research, LTD
Other
Eligibility
12 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
16
States / cities
Santa Rosa, California • Denver, Colorado • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Sep 24, 2026, 4:04 PM EDT
Not yet recruiting Not applicable Interventional

A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus Used for Keratoplasty in Keratoconus Patients

NCT04584125
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light, Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light
Drug
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 24, 2026, 4:04 PM EDT
Withdrawn Not applicable Interventional

Higher Irradiance in Keratoconus Ectasia

NCT01789333
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
UVA Light with irradiance exposure of 9 mW/cm2, Riboflavin 0.1% ophthalmic solution
Device · Drug
Lead sponsor
Stephen Trokel
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 24, 2026, 4:04 PM EDT
Recruiting Phase 2Phase 3 Interventional

Corneal Crosslinking for Treatment of Corneal Neovascularization

NCT04787471
View directory record Official record
Conditions
Corneal Neovascularization
Interventions
30 minute photoactivation of riboflavin 0.1%, 10 minute photoactivation of riboflavin 0.1%
Combination Product
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 24, 2026, 4:04 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Treatment of Keratoconus Using Collagen Cross-Linking

NCT00841386
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin-5-phosphate, Sham cross-linking
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
16 Years to 35 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Amherst, New York • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2009 · Synced Sep 24, 2026, 4:04 PM EDT
Recruiting Phase 2 Interventional

ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty

NCT06753916
View directory record Official record
Conditions
Corneal Transplant Failure
Interventions
Corneal Donor Tissue with Cross Linking, Corneal Donor Tissue without Cross Linking
Procedure
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
12
States / cities
Irvine, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 24, 2026, 4:04 PM EDT
No Longer Available No phase listed Expanded access Accepts healthy volunteers

Progressive Keratoconus or Ectasia Treatment Plan

NCT01384773
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Riboflavin Solution, UV-X Illumination System
Other · Device
Lead sponsor
Stephen Trokel
Other
Eligibility
16 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 24, 2026, 4:04 PM EDT
Terminated Not applicable Interventional Results available

Cross Linking for Treatment of Corneal Infection

NCT00912509
View directory record Official record
Conditions
Infectious Keratitis
Interventions
riboflavin, UVX Light
Drug · Device
Lead sponsor
Price Vision Group
Industry
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Corneal Collagen Cross-linking for Progressive Keratoconus

NCT00647699
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
riboflavin ophthalmic solution, UVA Irradiation
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
14 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
La Jolla, California • San Diego, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 24, 2026, 4:04 PM EDT
Not listed Phase 1 Interventional

Study of the Safety and Effectiveness of Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2

NCT02009709
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin 0.1% ophthalmic solution, CCL-VARIO UV lamp, CCL-VARIO at 18 mW/cm2
Drug · Device
Lead sponsor
Robert Mack, M.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Hoffman Estates, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 24, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Cross-linking for Corneal Ulcers Treatment Trial

NCT02570321
View directory record Official record
Conditions
Corneal Ulcer, Infectious Keratitis, Bacterial Ulcer, Fungal Ulcer
Interventions
Corneal Cross-linking, Anti Fungal Drug
Procedure · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 24, 2026, 4:04 PM EDT